IP Library Granted Patent US 7,932,235
Granted Patent B2
US 7,932,235 · App. 11/941,925 · Granted Apr 26, 2011

Triazolyl tropane derivatives

Assignee: Concert Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,235
App. No.
11/941,925
Granted
Apr 26, 2011
Kind
B2
Abstract

This invention relates to novel triazolyl tropane derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by blocking or reducing the binding ability of the CCR5 receptor.

Claims (85)

1. A compound of formula II:

or a salt, thereof; wherein:

each Y is independently selected from hydrogen or deuterium;

each Z is independently selected from hydrogen or deuterium; and

wherein each Y 1 is deuterium and each Y 2 is deuterium.

2. The compound of claim 1 , wherein each Z bound to the same carbon atom is the same.

3. The compound of claim 2 , wherein each Z is hydrogen.

4. The compound of claim 2 , wherein each member of at least one pair selected from Z 1 and Z 2 ; Z 3 and Z 4 ; Z 5 and Z 6 ; or Z 7 and Z 8 is simultaneously deuterium.

5. The compound of claim 1 , selected from any one of compounds set forth in the table below:

Cmpd

Y 1a

Y 1b

Y 2a

Y 2b

Y 2c

Z 1

Z 2

Z 3

Z 4

Z 5

Z 6

Z 7

Z 8

203

D

D

D

D

D

H

H

H

H

H

H

H

H

206

D

D

D

D

D

D

D

D

D

D

D

D

D

209

D

D

D

D

D

D

D

H

H

H

H

D

D

212

D

D

D

D

D

H

H

D

D

D

D

H

H.

or a pharmaceutically acceptable salt thereof.

6. The compound

or a pharmaceutically acceptable salt, thereof.

7. The compound of claim 1 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.

8. A pyrogen-free composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, thereof; and an acceptable carrier.

9. The composition of claim 8 formulated for pharmaceutical administration, wherein the carrier is a pharmaceutically acceptable carrier.

Assignments (2)
MERGER Recorded Aug 2, 2023
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 064465/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2008
From: TUNG, ROGER
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 020680/0479 →
Continuity (2)
Provisional Application 60859881 · Nov 17, 2006
Related Publication 20080161264A1 · Jul 3, 2008